Showing 3081-3090 of 4063 results for "".
- TFOS Recognizes the Bioprotectant Properties of Trehalose, a Component of Thealoz Duo, in the Treatment of Dry Eyehttps://modernod.com/news/tfos-recognizes-the-bioprotectant-properties-of-trehalose-a-component-of-thealoz-duo-in-the-treatment-of-dry-eye/2480223/The TFOS international Dry Eye WorkShop II (TFOS DEWS II), whose report has been published in the July 2017 issue of the Ocular Surface journal, acknowledged that trehalose is an effective ingredient in association with hyaluronic acid for the tre
- Novartis Confirms 2018 Targets as Alcon Recovery Gains Steamhttps://modernod.com/news/novartis-confirms-2018-targets-as-alcon-recovery-gains-steam/2480224/Swiss drugmaker Novartis’ first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit, according to a
- EyePoint Pharmaceuticals’ Yutiq for Posterior Segment Uveitis to be Presented at the 2018 ARVO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-yutiq-for-posterior-segment-uveitis-to-be-presented-at-the-2018-arvo-annual-meeting/2480232/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophtha
- Zepto Receives Award for Best Capsulotomy Technology 2017https://modernod.com/news/zepto-receives-award-for-best-capsulotomy-technology-2017/2480270/Mynosys Cellular Devices has announced that its flagship automated capsulotomy device, »Zepto, has been selected as the best capsulotomy technology by Cataract and Refrac
- Burnout Rising Among VA Optometrists, New Study Warnshttps://modernod.com/news/burnout-rising-among-va-optometrists-new-study-warns/2486597/Key Takeaways Burnout among VA optometrists increased substantially from 2018 to 2024, approaching nearly half of providers in recent years
- Nordic Pharma Announces European Launch of Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-announces-european-launch-of-lacrifill-canalicular-gel/2485691/Nordic Group, the parent company of Nordic Pharma, announced the European launch of Lacrifill, a novel therapy for the management of dry eye disease. Following CE mark approval in April 2025, Lacrifill is now available to healthcare professionals and patients acros
- FDA Approves Yuvezzi, First Dual-Agent Eye Drop for Presbyopiahttps://modernod.com/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia/2485503/Tenpoint Therapeutics announced that the FDA has approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults. Previously known as Brimochol PF, Yuvezzi is the first and only FDA-approved dual-agent
- Orbis International Appoints Kathleen Sherwin as New President and CEOhttps://modernod.com/news/orbis-international-appoints-kathleen-sherwin-as-new-president-and-ceo/2485326/Global nonprofit organization Orbis International has named Kathleen Sherwin as its new President and Chief Executive Officer, effective immediately. Ms. Sherwin arrives at Orbis with more than 25 years of leadership experience
- New International Myopia Guidance Urges Early, Personalized Carehttps://modernod.com/news/new-international-myopia-guidance-urges-early-personalized-care/2485288/The International Myopia Institute (IMI) has published its 2025 Digest, delivering the latest evidence-based guidance on myopia. The Dige
- Exploring a Connection Between GLP-1 Drugs and Vision Losshttps://modernod.com/news/exploring-a-connection-between-glp-1-drugs-and-vision-loss/2484306/Two studies presented at the 2025 AAO Annual Meeting explored a possible connection between GLP-1 drugs and vision loss. Using data from the World Health Organization’s global database of drug safety reports, researchers at the University of Ottawa Eye Institute, University of Tor